

(use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Application Number	Unassigned
--------------------	------------

Filing Date	Filed Herewith 10/31/03
-------------	-------------------------

First Named Inventor	Schenk, Dale B.
----------------------	-----------------

Art Unit	Unassigned-1647
----------	-----------------

Examiner Name	Unassigned	NICHOLS
---------------	------------	---------

Attorney Docket Number	015270-008920US
------------------------	-----------------

[illegible][illegible]

**Examiner
Signature**

Date Considered _____

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	Unassigned	
			Filing Date	Filed Herewith 10/31/03	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	Unassigned 1647	
			Examiner Name	Unassigned NICHOLS	
Sheet	2	of	3	Attorney Docket Number	015270-008920US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AG		CHAPMAN, P.F., "Model behaviour," <i>Nature</i> , 408:915-916 (2000).	
AH		CONWAY et al., "Acceleration of oligomerization, not fibrillization, is a shared property of both α -synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy," <i>PNAS</i> , 97(2):571-576 (2000).	
AI		DEMATTO et al., "Peripheral anti A β antibody alters CNS and plasma A β clearance and decreases brain A β burden in a mouse model of Alzheimer's disease," <i>PNAS</i> , 10:1-6 (2001).	
AJ		ELAN, "Elan and AHP provide an update on the phase 2A Clinical Trial of AN-1782," Press Release of 1/28/02.	
AK		ELAN, "Elan and Wyeth provide update on status of Alzheimer's collaboration," Press Release of 3/1/02.	
AL		ESIRI, M.M., "Is an effective immune intervention for Alzheimer's disease in prospect?," <i>Trends in Pharmacological Sciences</i> , 22(1):2-3 (Jan. 2001)	
AM		FRENKEL et al., "N-terminal EFRH sequence of Alzheimer's β -amyloid peptide represents the epitope of its anti-aggregating antibodies," <i>Journal of Neuroimmunology</i> , 88:85-90 (1998).	
AN		FRENKEL et al., "Immunization against Alzheimer's β -amyloid plaques via EFRH phage administration," <i>PNAS</i> , 97(21):11455-11459 (2000).	
AO		FRENKEL et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β -amyloid peptide is essential for modulation of fibrillar aggregation," <i>Journal of Neuroimmunology</i> , 95:136-142 (1999).	
AP		FRIEDLAND et al., "Neuroimaging of Vessel Amyloid in Alzheimer's Disease a,b," from <i>Cerebrovascular Pathology in Alzheimer's Disease</i> , eds. de la Torre and Hachinski, New York Academy of Science, NY, NY, pages 242-247 (1997).	
AQ		GAMES et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β -amyloid precursor protein," <i>Nature</i> , 373(6514):523-527 (1995).	
AR		GRUBECK-LOEBENSTEIN et al., "Immunization with β -amyloid: could T-cell activation have a harmful effect?," <i>TINS</i> , 23(3):114 (2000).	
AS		JEN et al., "Preparation and purification of antisera against different regions or isoforms of β -amyloid precursor protein," <i>Brain Research Protocols</i> , 2:23-30 (1997).	
AT		JOBLING et al., "Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis," <i>Molecular Microbiology</i> , 5(7):1755-1767 (1991).	
AU		LEMERE et al., "Nasal A β Treatment Induces Anti-A β Antibody Production and Decreases Cerebral Amyloid Burden in PD-APP Mice," <i>Annals of NY Acad. Sci.</i> , 920:328-331 (2000).	
AV		MASLIAH et al., " β -Amyloid peptides enhance α -synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease," <i>PNAS</i> , 98(21):12245-12250 (2001).	


Examiner Signature	<i>[Signature]</i>	Date Considered	3/22/05
--------------------	--------------------	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	Unassigned	
			Filing Date	Filed Herewith 10/31/03	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	Unassigned 16A7	
			Examiner Name	Unassigned NICHOLS	
Sheet	3	of	3	Attorney Docket Number	015270-008920US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AW	PERUTZ et al., "Amyloid fibers are water-filled nanotubes," <u>PNAS</u> , 99(8):5591-5595 (2002).		
AX	RASO, V., "Immunotherapy of Alzheimer's Disease," <u>Immunotherapy Weekly</u> , abstract, (1999).		
AY	SCHENK et al., "Immunization with amyloid- β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," <u>Nature</u> , 400:173-177 (1999).		
AZ	SKOLNICK et al., "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <u>Trends in Biotechnology</u> , 18(1):34-39 (2000).		
BA	SMALL et al., "Alzheimer's disease and A β toxicity: from top to bottom," <u>Nat. Rev. Neurosci.</u> , 2(8):595-598 (2001).		
BB	ST GEORGE-HYSLOP et al., "Antibody clears senile plaques," <u>Nature</u> , 400:116-117 (1999).		
BC	YOUNKIN, S.G., "Amyloid β vaccination: reduced plaques and improved cognition," <u>Nature Medicine</u> , 7(1):18-19 (2001).		

Examiner Signature		Date Considered	3/22/05
-----------------------	---	--------------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English Language Translation is attached.

Substitution for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
Sheet				Application Number	
1				10/699,517	
of				Filing Date	
2				October 31, 2003	
				First Named Inventor	
				Schenk, Dale B.	
				Art Unit	
				4646 / 647	
				Examiner Name	
				Unassigned - Nichols	
				Attorney Docket Number	
				015270-008920US	

[illegible][illegible]

Examiner Signature	<i>[Signature]</i>	Date Considered	3/22/05
-----------------------	--------------------	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Institute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/699,517	
			Filing Date	October 31, 2003	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1645 1647	
			Examiner Name	Unassigned- NICHOLS	
Sheet	2	of	2	Attorney Docket Number	015270-008920US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CS	AF	BODLES et al., "Toxicity of non-A β component of Alzheimer's disease amyloid, and N-terminal fragments thereof, correlates to formation of β -sheet structure and fibrils," <u>Eur J. Biochem.</u> , 267:2186-2194 (2000).	
	AG	CAO et al., "Development of an Alpha Synuclein Recombinant Protein as a Potential Candidate Against Parkinson's Disease," Program No. 594.13, Abstract Viewer/Itinerary Planner, Washington D.C.: Society for Neuroscience, 2002.	
	AH	CULVENOR et al., "Non-A β Component of Alzheimer's Disease Amyloid (NAC) Revisited, NAC and α -Synuclein Are Not Associated with A β Amyloid," <u>Am. J. Pathology</u> , 155(4):1173-1181 (1999).	
	AI	HASHIMOTO et al., "Alpha-synuclein in Lewy Body Disease and Alzheimer's Disease," <u>Brain Pathology</u> , 9:707-720 (1999).	
	AJ	HSU et al., "A-Synuclein Promotes Mitochondrial Deficit and Oxidative Stress," <u>Am. J. Pathology</u> , 157(2):401-410 (2000).	
	AK	JENSEN et al., "Residues in the synuclein consensus motif of the alpha-synuclein fragment, NAC, participate in transglutaminase-catalysed cross-linking to Alzheimer-disease amyloid beta A4 peptide," <u>Biochem. J.</u> , 310(Pt 1):91-94 (1995).	
	AL	MASLIAH et al., "Dopaminergic Loss and Inclusion Body Formation in α -Synuclein Mice: Implications for Neurodegenerative Disorders," <u>Science</u> , 287:1265-1268 (2000).	
	AM	NCBI database search result for P37840 Alpha-synuclein conducted 10/21/02 at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&DB=protein&list_uids=58	
	AN	NCBI database search result for NP_009292 synuclein, alpha conducted 10/21/02 at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=protein&list_uids=68	
CS	AO	UEDA et al., "Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease," <u>PNAS</u> , 90:11282-11286 (1993).	

Examiner Signature		Date Considered	3/22/05
--------------------	--	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.